Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi/Regeneron Get Reprieve: Praluent Can Stay On Market For Now

Executive Summary

Federal Circuit stays injunction that would have halted sales of the PCSK9 inhibitor on Feb. 21; stay extends through appeal of injunction and patent verdict.


Related Content

Praluent Lives On As US Court Vacates Amgen's PCSK9 Patent Win
Praluent Injunction Goes Unmentioned At PCSK9 Patent Case Appeal
PCSK9 Sponsors Still Face Challenges In Turning Around Dismal Launches
PSCK9 Battle: Sanofi Not Negotiating Praluent Fate With Amgen; Ruling Possible By June
Amgen’s Repatha Passes CVOT Test, But Contribution To 2017 Sales Growth Unclear
PCSK9 Patent Fight: Amgen Opposes Doctor Efforts To Keep Praluent On Market
‘Between A Rock And A Hard Place,’ Court Issues Injunction To Halt Praluent Sales
Praluent Fate Uncertain After Amgen Wins PCSK9 Patent Battle


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts